Results 51 to 60 of about 14,257 (250)

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna, Chanchhaya, Ngeth, Ferradini, Laurent, Narom, Prak, Nerrienet, Eric, Pujades-Rodríguez, Mar, Schramm, Birgit, Som, Leakena   +7 more
core   +2 more sources

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models

AIDS Research and Therapy, 2009
Background Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important category of drugs for both chemotherapy and prevention of human immunodeficiency virus type 1 (HIV-1) infection.
Emau Peter, Agy Michael B, Saifuddin Mohammed, Tian Baoping, Jiang Yonghou, Cairns J Scott, Tsai Che-Chung   +6 more
doaj   +1 more source

Molecular dynamics simulations and docking of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a possible approach to personalized HIV treatment : from 7th German Conference on Chemoinformatics: 25 CIC-Workshop Goslar, Germany, 6 - 8 November 2011 [PDF]

, 2012
The human immunodeficiency virus (HIV) is currently ranked sixth in the worldwide causes of death [1]. One treatment approach is to inhibit reverse transcriptase (RT), an enzyme essential for reverse transcription of viral RNA into DNA before integration
Bender, Andreas, Bond, Peter J., Korb, Oliver, Mäntele, Werner, Roessler, Florian D.   +4 more
core  

Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase [PDF]

, 2014
Using a computationally driven approach, a class of inhibitors with picomolar potency known as the catechol diethers were developed targeting the non-nucleoside-binding pocket of HIV-1 reverse transcriptase.
Anderson, Karen S., Bollini, Mariela, Frey, Kathleen M., Gallardo Macias, Ricardo, Gray, William T., Jorgensen, William L., Spasov, Krasimir A.   +6 more
core   +1 more source

Psychological responses to interval and continuous exercise in people living with HIV: A single‐blind, counterbalanced, crossover study

HIV Medicine, EarlyView.
Abstract Aim This study compared acute psychological responses to a single session of low‐volume high‐intensity interval exercise (HIIE‐LV), high‐volume high‐intensity interval exercise (HIIE‐HV), and moderate‐intensity continuous exercise (MICE) in people living with HIV, and healthy controls using a randomized, counterbalanced crossover design ...
Phelipe Wilde, Victor S. de Queiros, Jason R. Jaggers, Angelo Sabag, Júlio M. Alves, Elaine Fernandes, Roberto F. C. Rocha, Paulo F. de Almeida‐Neto, Ronaldo Vagner Thomatieli‐Santos, Paulo Moreira Silva Dantas   +9 more
wiley   +1 more source

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Drugs in Context, 2019
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to ...
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano   +3 more
doaj   +1 more source

Genetic mechanisms of resistance to NRTI and NNRTI [PDF]

HIV Clinical Trials, 2002
Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) seems to develop following three different pathways. Discriminatory mutations favor the binding of physiologic nucleosides over that of drugs. The newly so-called nucleoside-associated mutations (NAMs) enhance the removal of chain terminators (pyrophosphorolysis) from the cDNA in ...
Vincent, Soriano, Carmen, de Mendoza
openaire   +2 more sources

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

HIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre, Antoine Gross, Alain Makinson   +2 more
wiley   +1 more source

Review The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Viruses, 2014
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.
Nicolas Sluis-Cremer
doaj   +1 more source